Literature DB >> 10622521

Validation of an instrument to measure voice-related quality of life (V-RQOL).

N D Hogikyan1, G Sethuraman.   

Abstract

When a patient presents for care of a voice disorder, the clinician attempts to diagnose the problem, quantify the degree of dysphonia, and prescribe appropriate treatment. Quantification of the degree of dysphonia is often difficult, as no universal index of vocal function exists. Decisions about the nature and intensity of treatment are often based on the magnitude of the voice-related problems experienced by the patient and the importance that the patient places on those problems, that is, the impact that the voice disorder is having on the patient's voice-related quality of life (V-RQOL). Measurement of post-treatment outcome is also not standardized. Regardless of how the clinician measures response to treatment, it will typically be measured by the patient in terms of how his or her voice-related problems are affected by the treatment. Measurement of quality of life has not been a traditional part of the evaluation of the dysphonic patient. This study was undertaken to develop and validate an instrument for measuring V-RQOL using a population of 109 voice and 22 non-voice patients. The 10-item V-RQOL measure performs well in tests of reliability, validity, and responsiveness, and it carries a low burden. Measurement of V-RQOL is a valuable addition to the evaluation of dysphonic patients and their treatment outcomes.

Entities:  

Mesh:

Year:  1999        PMID: 10622521     DOI: 10.1016/s0892-1997(99)80010-1

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  143 in total

1.  Validation and cultural modification of Arabic voice handicap index.

Authors:  Khalid H Malki; Tamer A Mesallam; Mohamed Farahat; Manal Bukhari; Thomas Murry
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-09       Impact factor: 2.503

Review 2.  Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancers.

Authors:  Katherine A Hutcheson; Jan S Lewin
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  Voice handicap index and voice-related quality of life in small laryngeal carcinoma.

Authors:  C Kasper; M Schuster; G Psychogios; J Zenk; A Ströbele; F Rosanowski; E Grässel; T Haderlein
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-07       Impact factor: 2.503

4.  Coping and quality of life after total laryngectomy.

Authors:  Tanya L Eadie; Brianne C Bowker
Journal:  Otolaryngol Head Neck Surg       Date:  2012-02-03       Impact factor: 3.497

5.  [Grading of the Voice Handicap Index].

Authors:  E Grässel; U Hoppe; F Rosanowski
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 6.  [Therapy for unilateral vocal fold palsy].

Authors:  M Schuster; U Eysholdt
Journal:  HNO       Date:  2005-09       Impact factor: 1.284

7.  Measuring communicative participation: a review of self-report instruments in speech-language pathology.

Authors:  Tanya L Eadie; Kathryn M Yorkston; Estelle R Klasner; Brian J Dudgeon; Jean C Deitz; Carolyn R Baylor; Robert M Miller; Dagmar Amtmann
Journal:  Am J Speech Lang Pathol       Date:  2006-11       Impact factor: 2.408

8.  Correlation between coping strategies and subjective assessment of the voice-related quality of life of patients after resection of T1 and T2 laryngeal tumours.

Authors:  E Seiferlein; T Haderlein; M Schuster; E Gräßel; C Bohr
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-04-27       Impact factor: 2.503

9.  [Voice Handicap Index (VHI) in inpatient voice rehabilitation medicine].

Authors:  R Machulla; T Hacki; U Hoppe; F Rosanowski
Journal:  HNO       Date:  2006-01       Impact factor: 1.284

10.  The effect of obstructive sleep apnea syndrome and continuous positive airway pressure treatment on voice performance.

Authors:  Doğan Atan; Kürşat Murat Özcan; Aykut İkincioğulları; Sabri Köseoğlu; Mehmet Ali Çetin; Serdar Ensari; Hüseyin Dere
Journal:  Sleep Breath       Date:  2014-12-09       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.